Results 61 to 70 of about 82,297 (250)

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source

Global Trends and Advances in Traumatic Brain Injury

Brain Health, EarlyView.
ABSTRACT Traumatic brain injury (TBI) remains a major global public health challenge, contributing substantially to morbidity and mortality while imposing a significant socioeconomic burden. In recent years, notable progress has been made in understanding TBI pathophysiology, classification, monitoring, and treatment.
Yuan Zhuang, Xixian Liao, Jiyao Jiang, Guoyi Gao   +3 more
wiley   +1 more source

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia.
Nur Aini Hasan, Viskasari Pintoko Kalanjati, Kusuma Eko Purwantari, Abdurachman Abdurachman, Muhammad Miftahussurur   +4 more
doaj   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?

European Journal of Medical Research, 2023
Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations.
Mohammed G. Maslub, Mahasen A. Radwan, Nur Aizati Athirah Daud, Abubakar Sha’aban   +3 more
doaj   +1 more source

Statin use and adverse effects among adults \u3e 75 years of age: Insights from the Patient and Provider Assessment of Lipid Management (PALM) registry [PDF]

, 2018
Background: Current statin use and symptoms among older adults in routine community practice have not been well characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline.
Goldberg, Anne C, Lee, L. Veronica, Louie, Michael J, Mi, Xiaojuan, Nanna, Michael G, Navar, Ann Marie, Peterson, Eric D, Robinson, Jennifer, Roger, Veronique L, Virani, Salim S, Wang, Tracy Y   +10 more
core   +2 more sources

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

Clinical Pharmacology &Therapeutics, EarlyView.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel, Anina Zumtaugwald, Anna Bollinger, Chiara Jeiziner, Kurt E. Hersberger, Florine Wiss, Markus L. Lampert, Samuel S. Allemann, Henriette E. Meyer zu Schwabedissen, Céline K. Stäuble   +9 more
wiley   +1 more source

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. [PDF]

, 2010
A large body of evidence suggests that, besides their cholesterol-lowering effect, statins exert anti-inflammatory action. Consequently, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis.
BRESCIA MORRA, VINCENZO, BRUNETTI, ARTURO, CAROTENUTO, BARBARA, LANZILLO, ROBERTA, Lus G, OREFICE, GIUSEPPE, Prinster A, Quarantelli M, RINALDI, CARLO, SALVATORE, ELENA, Spitaleri D, Tedeschi G, Vacca G, Ventrella G   +13 more
core   +1 more source

1,1‐Disubstituted Vinylbromides: Versatile Building Blocks for the Synthesis of Nitrogen‐Containing Heterocycles

European Journal of Organic Chemistry, EarlyView.
1,1‐Disubstituted vinylbromides are key intermediates for constructing nitrogen‐containing heterocycles. This review provides an overview of the synthetic applications of 1,1‐disubstituted vinylbromides and summarizes recent developments in reaction methodologies, mechanistic insights, and the structural diversity of N‐heterocyclic compounds accessible
Anne Westermeyer, Jun Fang, Chonghuo Liu, Guillaume Lefèvre, Gérard Guillamot, Phannarath Phansavath, Virginie Ratovelomanana‐Vidal   +6 more
wiley   +1 more source